{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"RPh2D/Maximum Tolerated Dose (MTD) of Selinexor when used in combination with high-dose melphalan as a conditioning regimen for hematopoietic cell transplant. MTD: the highest dose level at which 1 or less of 6 participants experience a dose limiting toxicity (DLT).","groups":[{"description":"The conditioning regimen begins 3 days prior to autologous transplant. Day 0 is the day of the autologous hematopoietic cell transplant. Melphalan will be given intravenously (IV) on Day -3 and Day -2; Dexamethasone will be given through via IV on Day -3, Day -2 and Day -1; fosaprepitant at 150 IV on days -3 and -2 will be given to patients an an antiemetic.Selinexor will be taken by mouth (PO) daily on the same day participants receive chemotherapy with melphalan.\n\nSelinexor: Selinexor will be given orally 2 to 3 hours prior to high dose-melphalan IV infusion. Phase I: Dose escalation beginning with 40 mg to determine the recommended Phase II dose (RPh2D). Phase II: Treatment at RPh2D.\n\nMelphalan: Melphalan 100 mg/m\\^2 IV over 30-45 minutes.\n\nDexamethasone: Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).\n\nAutologous Hematopoietic Cell Transplantation (HCT): Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy.\n\nFosaprepitant: Fosaprepitant at 150 mg IV on days -3 and -2.","id":"OG000","title":"Selinexor Plus HDM HCT"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 3 months","title":"Phase I: Recommended Phase II Dose (RPh2D)","type":"PRIMARY","unitOfMeasure":"mg"}